MétaCan
Menu
← Retour à la cohorte
Enregistrement W3014082077 · doi:10.1158/1538-7445.sabcs19-p3-07-08

Abstract P3-07-08: Comparison of MammaTyper® RT-qPCR based subtyping with simulated breast cancer prognostic signatures

2020· article· en· W3014082077 sur OpenAlexaff
Mark Laible, Sebastian Aulmann, A. Etzrodt, Marcus Schmidt, Cheryl Crozier, Ralph Wirtz, Jane Bayani, Uğur Şahin, John M.S. Bartlett

Notice bibliographique

RevueCancer Research · 2020
Typearticle
Langueen
DomaineBiochemistry, Genetics and Molecular Biology
ThématiqueMolecular Biology Techniques and Applications
Établissements canadiensOntario Institute for Cancer Research
Organismes subventionnairesnon disponible
Mots-clésSubtypingBreast cancerOncologyPairwise comparisonInternal medicineCancerMedicineArtificial intelligenceComputer science

Résumé

récupéré en direct d'OpenAlex

Abstract Background: Current prognostic signatures are based on measurements of numerous targets and require specialized equipment and complex calculations. While the overall prognostic capabilities of the tests may be comparable in ER+/HER2- breast cancer, side by side comparisons of different tests have shown that results differ on the individual patient level (Bartlett et al., JNCI, 2016). Here we determined risk scores and classifications in 160 tumors to the following commercial and academic prognostic tests using a custom gene panel for which the publically available algorithms were trained against the actual commercial test scores: Mammaprint®, Oncotype DX®, Prosigna® including PAM50 subtyping; and academic risk scores: IHC4-like, 95-gene score and the Genomic Grade Index. These trained risk classifiers were compared to the results of the MammaTyper® IVD-kit. Methods: RNA was extracted from FFPE tissue sections and analyzed on the Nanostring nCounter® using a probe set containing all targets and reference genes used in the original signatures (N=199). Nanostring measurements and calculations of simulated risk classifiers were carried out as described previously (Bayani et al., npj Breast Cancer, 2017) and retrained against actual commercial test scores (Bartlett et al., in prep.). MammaTyper® RT-qPCR of ERBB2, ESR1, PGR and MKI67 (normalized to CALM2) was carried out on a separate aliquot of the same RNA sample. St. Gallen surrogate subtypes were assigned based on binary mRNA expression according to pre-defined cutoffs. For calculating pairwise agreements between test categorizations, simulated test results with ternary classification were transformed to binary classifications (IHC4-like: low + int vs. high, Oncotype DX-trained: RS≤25 vs. RS>25, Prosigna-trained ROR-P: low vs. int + high). Comparison of MammaTyper® with simulated risk scores was done on the level of surrogate subtypes and on the level of continuous MKI67 and LRP score values. The MammaTyper® LRP score is a previously developed signature to predict RS ≤25 results with high specificity. Results: Marker positivity rate by RT-qPCR was 83% for ESR1, 72% for PGR, 9% for ERBB2 and 58% for MKI67 based on the pre-specified MammaTyper® cutoffs. The highest rate of low risk results was found for binary RS classification with 68.1% of RS ≤25 samples. MammaTyper® Luminal A-like result was found in 30.6% of samples a rate similar to ROR-P, Genomic Grade Index or MammaPrint-trained low risk results (35.0%, 38.1% and 38.8% respectively). The highest agreement between the simulated risk classifications was observed between binary OncotypeDX-trained RS and IHC4-like classifications with 93.1%. Prosigna-trained (ROR-P) and IHC4-like score had the lowest pairwise agreement with only 65.0% agreement. Oncotype DX-trained and the 95 gene score had the highest concordance to MammaTyper® Luminal A-like subtype with 100% and 96% of Luminal A-like samples classified as RS ≤25 and low risk also by these signatures, respectively. ROC analyses of MammaTyper®MKI67 against binary 95-gene score risk classifier resulted in an AUC of 0.949. The lowest AUC for MKI67 was achieved against simulated MammaPrint-trained classification (AUC=0.874). When applying the LRP score to ROC analysis, almost identical AUCs were achieved for IHC4-like and binary Oncotype DX-trained classifications with AUCs of 0.976 and 0.969 respectively. Conclusion: Low cost local RT-qPCR measurements by MammaTyper® show a high agreement with the scores generated by our Oncotype DX-trained scores. The academic and well validated 95-gene signature agrees well with MammaTyper®MKI67 single gene measurement. Therefore, the locally performed MammaTyper® test may serve as cost effective surrogate for complex prognostic signatures or at least enables a pre-screening for molecularly “obviously” low risk samples. Citation Format: Mark Laible, Sebastian Aulmann, Alfred Etzrodt, Marcus Schmidt, Cheryl Crozier, Ralph Wirtz, Jane Bayani, Ugur Sahin, John MS Bartlett. Comparison of MammaTyper® RT-qPCR based subtyping with simulated breast cancer prognostic signatures [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-07-08.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,002
score de la tête « metaresearch » (Gemma)0,004
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Simulation ou modélisation · Signal consensuel: aucune
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,002
Score d'incertitude au seuil0,011

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0020,004
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0000,000
Bibliométrie0,0000,000
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,000
Charge utile insuffisante (le modèle a refusé de juger)0,0020,001

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,053
Tête enseignante GPT0,398
Écart entre enseignants0,345 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeSimulation ou modélisation
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations0
Publié2020
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueCancer Research→Même sujetMolecular Biology Techniques and Applications→Travaux en français237 207→